Postgraduate Program in Health and Nutrition, Federal University of Ouro Preto, Ouro Preto, Minas Gerais, Brazil.
Department of Physical Education, Federal Institute of Southeast Minas Gerais - Campus Rio Pomba, Rio Pomba, Minas Gerais, Brazil.
Arch Gerontol Geriatr. 2024 Feb;117:105182. doi: 10.1016/j.archger.2023.105182. Epub 2023 Sep 7.
The aim of this study was to verify the association of the ACTN3-R577X polymorphism with sarcopenia stage, according to the Revised European Consensus on the Definition and Diagnosis of Sarcopenia, in middle-aged and older adults, pre- and post- ST. In the 12-week longitudinal study, 71 middle-aged and older adults were evaluated; the participants were assigned to either control or intervention group. The intervention group underwent progressive ST three times a week. All participants underwent blood collection, DNA extraction, genotyping of the ACTN3-R577X polymorphism, anthropometric evaluations, and diagnostic tests for sarcopenia. The last two tests were repeated after 12 weeks. No association of the ACTN3-R577X polymorphism with sarcopenia stage was observed before and after 12 weeks. However, the intervention group remained non-sarcopenic (n = 25, p <0.05) or achieved changes in sarcopenia stage (from sarcopenic to non-sarcopenic) (n = 13, p <0.05). Our study demonstrates that progressive ST performed regularly can reverse or prevent sarcopenia regardless of genotype for the ACTN3-R577X polymorphism.
本研究旨在验证 ACTN3-R577X 多态性与根据修订后的欧洲肌少症定义和诊断共识定义的肌少症分期之间的关联，研究对象为中年及以上成年人，包括 ST 治疗前后。在为期 12 周的纵向研究中，共评估了 71 名中年及以上成年人；参与者被分配到对照组或干预组。干预组每周进行三次渐进式 ST 治疗。所有参与者均进行了血液采集、DNA 提取、ACTN3-R577X 多态性基因分型、人体测量评估和肌少症诊断测试。12 周后重复进行后两项测试。在 12 周前后，均未观察到 ACTN3-R577X 多态性与肌少症分期之间存在关联。然而，干预组仍保持非肌少症状态（n=25，p<0.05）或肌少症分期发生变化（从肌少症转为非肌少症）（n=13，p<0.05）。我们的研究表明，无论 ACTN3-R577X 多态性的基因型如何，定期进行渐进式 ST 治疗可以逆转或预防肌少症。
